{"organizations": [], "uuid": "e25d36333e0d004a55a834514a341fb13a2e5b12", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-clears-pluristems-expanded-acc/brief-fda-clears-pluristems-expanded-access-program-to-initiate-treatments-of-critical-limb-ischemia-idUSASB0C0BN", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T14:20:00.000+02:00", "replies_count": 0, "uuid": "e25d36333e0d004a55a834514a341fb13a2e5b12"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-clears-pluristems-expanded-acc/brief-fda-clears-pluristems-expanded-access-program-to-initiate-treatments-of-critical-limb-ischemia-idUSASB0C0BN", "ord_in_thread": 0, "title": "BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "pluristem therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "treatments of critical limb ischemia reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 9, 2018 / 12:22 PM / in 10 minutes BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia Reuters Staff 1 Min Read \nJan 9 (Reuters) - Pluristem Therapeutics Inc: \n* PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO‘S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​ \n* FDA CLEARS PLURISTEM’S EXPANDED ACCESS PROGRAM TO INITIATE TREATMENTS OF CRITICAL LIMB ISCHEMIA OUTSIDE OF ONGOING PHASE III STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-09T14:20:00.000+02:00", "crawled": "2018-01-09T14:41:11.039+02:00", "highlightTitle": ""}